FebriDx® is the first and only rapid, point of care test that uses a capillary blood sample to identify and differentiate a clinically significant immune response to viral and/or bacterial acute respiratory infection.

TheFebriDx® test simultaneously detects elevated levels of Myxovirus resistance A (MxA) – a derivative of interferon that becomes elevated in the presence of acute viral infection, and C-reactive protein (CRP) – an acute phase protein that is elevated in the presence of bacterial infection.

The FebriDx® test can be used to help triage infectious patients at the point of care, providing clinicians with a clear path to diagnosis and treatment, leading to more efficacious healthcare decisions. Test results are available in 10 minutes, allowing a treatment plan to be established during the patient’s initial surgery visit.

Right diagnosis

  • Identify & triage patients suffering from a clinically significant ARI
  • Differentiate viral from bacterial infectious aetiology
  • Identify the need for pathogen-specific testing

Right treatment

  • Empower GPs to make targeted immune response-directed therapeutic decisions at the point of care
  • Reduce unnecessary antibiotic prescriptions and the possibility of antibiotic resistance, allergies and toxicities, and adverse events
  • Improve patient satisfaction by reducing healthcare costs associated with misdiagnosis, repeat visits, and mistreatment

Right now

  • Results in 10 minutes
  • Single use, disposable test
  • Provide optimal patient management during the initial consultation
Request product evaluation

FebriDx in the news…

NICE - Medtech Innovation Briefing: FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care

“All 3 specialist commentators considered that FebriDx could reduce the unnecessary prescription of antibiotics. Two noted that this might contribute to antimicrobial stewardship and the Global Strategy of Antimicrobial Resistance.”

Click here to view the briefing PDF
Click here to see the briefing at the NICE website